SCHEMBL3624974

SCHEMBL3624974

O=C(O)c1cc(Cl)cnc1-c1cccnc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.54
PTGS2 P35354 1/20 0.54
ALDH1A1 P00352 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
KMO O15229 2/20 0.48
MKNK1 Q9BUB5 3/20 0.46
MKNK2 Q9HBH9 3/20 0.46
DHODH Q02127 3/20 0.46
EIF4E P06730 1/20 0.45
CYP2A6 P11509 1/20 0.44
LMNA P02545 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HTT P42858 1/20 0.44
PIM1 P11309 1/20 0.43
GRIK1 P39086 1/20 0.43
HCRTR1 O43613 2/20 0.43
HCRTR2 O43614 2/20 0.43
HTR1A P08908 1/20 0.43
OPRM1 P35372 1/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3621439 0.83 MAPK1 (0.55) PTGS1PTGS2ALDH1A1HCRTR1HCRTR2
SCHEMBL5145882 0.80 KDM4E (0.67) PTGS2ALDH1A1L3MBTL1KMOMKNK1
Hydrochloric Acid SCHEMBL22719435 0.78 KDM4E (0.65) PTGS2ALDH1A1L3MBTL1KMOMKNK1
SCHEMBL30189226 0.78 DHODH (0.50) ALDH1A1KMODHODHPIM1SMN1; SMN2
SCHEMBL3618824 0.78 HCRTR1 (0.60) KMODHODHCYP2A6LMNAKDM4E
SCHEMBL21290342 0.77 SMN1; SMN2 (0.46) PTGS1PTGS2ALDH1A1L3MBTL1DHODH
SCHEMBL8518593 0.77 ALDH1A1 (0.49) ALDH1A1L3MBTL1KMOMKNK1MKNK2
SCHEMBL5111947 0.76 ALDH1A1 (0.56) PTGS2ALDH1A1KMODHODHEIF4E
SCHEMBL28852822 0.76 PTGS2 (0.67) PTGS1PTGS2CYP2A6PIM1
SCHEMBL28414743 0.75 PTGS1 (0.52) PTGS1PTGS2ALDH1A1MKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410142-B2 Bipyridine carboxamide orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2013-04-02 US disclosed
US-20100063056-A1 BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. 2010-03-11 US disclosed
EP-2131654-A1 BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2009-12-16 EP disclosed
WO-2008108991-A1 BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063056-A1 BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, CRHR1 PTGS1 1553/4885PTGS2 1664/4885ALDH1A1 3191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.